glp 1 agonist nash Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective Pharmacological Therapeutics: Current Trends for

Description

[DOI] [PubMed] [Google Scholar] 99.Knop F.K., Aroda V.R., do Vale R.D., Holst-Hansen T., Laursen P.N., Rosenstock J., Rubino D.M., Garvey W.T., OASIS 1 Investigators Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE )a multicentre, double-blind, randomised, placebo-controlled trial

Proposed mechanisms include reduced postprandial glucose excursions, potentially through delayed glucose absorption and modest increases in endogenous GLP-1 secretion, though human evidence remains limited and of low certainty

JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis

Quick Answer: Research suggests 5 to 10 grams of allulose may produce modest, transient increases in GLP-1 levels, though no minimum effective dose has been established and individual responses vary considerably